| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 93.74 | 24.4% | 31.3% |
| Total Income | 95.02 | 24.2% | 30.6% |
| Expenditure | 81.93 | 22.8% | 29.8% |
| PBT | 13.02 | 35.3% | 36.2% |
| Net Profit | 10.58 | 29.2% | 26.1% |
| OPM | 16.72% | 0.67pp | 1.26pp |
| NPM | 11.13% | 0.43pp | 0.40pp |
| EPS | 8.26 | 28.9% | 24.8% |
31% growth, margin lag; guided conservatively despite beat
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat revenue growth guidance (31% vs 20–25% range) but guided conservatively for full-year. EBITDA margin slight shortfall vs range; capex and capacity timelines credible.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Gala delivered strong Q2 results (31% revenue growth, ₹100+ Cr order book) but maintained FY27 guidance (20–25%) rather than raising it—a cautious stance that suggests management sees execution risk ahead. While the electrolyzer opportunity (₹40–50 Cr potential 2–3y) and capacity expansion (Chennai Phase 1/2, Wada land) provide long-term catalysts, near-term margin recovery lags guidance (16.7% vs 17–19% target), and working capital remains elevated. Recommend Hold pending Q3 delivery on Chennai ramp-up.
₹93.7 Cr
Revenue · +31.3% YoY₹10.6 Cr
Reported PAT · +26.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue growth 31% YoY, driven by volume + new components + new customer
METDelivered 93.7 Cr, +31.3% YoY. Breakdown: 3 pillars ~10% each (organic, new components, new customer).
Order book grew 44% YoY, crossed INR100 Cr for first time
METManagement cited >₹100 Cr order book as major milestone; 44% YoY growth is substantive.
PAT up 26% YoY at INR11 Cr, margins 11.31%
OVERSTATEDDelivered ₹10.6 Cr (+26.1% YoY), margin 11.1%. Management overstated by ~4% on absolute PAT.
EBITDA margin 16.76%, targeting 17–19% going forward
METDelivered OPM 16.7%, aligned. Guidance 17–19% is maintained from prior, not raised.
Chennai Phase 1 targeting ₹15 Cr revenue from Q3 onward; Phase 2 live Q4 FY27
METTimeline & revenue run-rate credible given capex milestones; Phase 2 capacity INR50 Cr.
On track for 25% revenue growth this year
METQ2 delivered 31%. Guidance range 20–25% maintained; statement aligns with mid-point of range.
Earnings quality
What changed since the last call
Electrolyzer entry — first bulk order secured
NewReceived ₹2 Cr order H1 FY27; discussing with 2 more suppliers. Opens ₹100+ Cr customer potential over 2–3y.
EBITDA margin guidance maintained at 17–19%
NeutralPrior call same range; Q2 delivered 16.7%. Management confident in gradual recovery via mix, manpower leverage, Chennai ramp.
Order book milestone: >₹100 Cr (first time)
UpgradeQ2 book 44% YoY growth. Reflects 3-pillar strategy: organic growth, new components from existing customers, new Tier-1 OEMs.
Land acquisition Wada: 10 acres secured, 3–5 more sought
NewWada MOU signed June 2026; legal finalization ongoing. Next 3–5 acres for Q3/Q4 FY28 capacity. SIPCOT approvals pending.
FY27 revenue growth guidance: maintained 20–25%
NeutralPrior guidance same range. Q2 beat at +31.3%, but management kept range unchanged for full-year (prudent, given cyclicality & macro uncertainty).
The Q&A
Analysts pressed on capacity utilization, working capital, and near-term vs multi-year growth inflection. Management held firm: detailed on capacity ramp (Phase 1 ₹15 Cr, Phase 2 ₹50 Cr timelines), transparent on inventory build rationale (export goods in transit, 25% volume growth), candid on margin headwinds (manpower costs offset product mix gains). No evasion; minor hedges on land approvals and government timelines. Overall tone: constructive, not defensive.
Capacity expansion plan — Aditya Pal, MSA Capital Partners
AnsweredCurrent INR450 Cr. Phase 2 at Chennai (10,000 sq ft mezzanine) adds INR50 Cr by Q4 FY27. Wada: 10 acres signed June 2026, to develop phased over 2–3 years, 2–3 stages. FY28 capex INR40–45 Cr covers land & initial builds.
Revenue breakdown & volume growth — Divyansh Gupta, Latent PMS
PartialThree pillars ~10% each: (1) organic volume growth, (2) new components from existing customers, (3) new customer entry. Price negligible. At 270 days inventory annually, ~100 days in quarter. Export 36%, import content high → goods-in-transit are inventory.
Electrolyzer opportunity — Ahaan, Individual Investor
AnsweredReceived 1st bulk order June 2026; INR2 Cr sales FY27. Discussing 2 more companies for sample development. Total potential INR40–50 Cr over 2–3 years (railways, offshore wind, mining safety). Already in advanced discussions with 1 export, 1 global electrolyzer company.
EBITDA margin trajectory — Vidhi Gandhi, Individual Investor
AnsweredProduct mix improvement, manpower cost reduction via automation, other expenses down 2.2%. H1 FY27 saw forex benefit (no loss in H1 vs H1 FY26 loss). Targeting 17–19% via further mix + manpower leverage as Chennai scales. Impact 1.3% improvement Q2.
Wind sector demand & market share — Lakan Chhabra, Individual Investor
AnsweredWind demand flat, but Gala gaining share from 5–25% to 25–30% with existing suppliers. Also: new product (bolt) approved; new markets (offshore, tower applications). Segment growing 25% YoY despite macro flatness; upside in offshore wind exports.
DSS capacity and utilization — Lakan Chhabra, follow-up
AnsweredAt 85% utilization currently. DSS + SFS capacity planned in new FY28 facility. Outsourcing options (machining, heat-treatment) also explored. Growth headroom available.
Working capital & KPMG optimization — Ahaan, Individual Investor
PartialKPMG completed diagnosis; report submitted. Will implement recommendations early FY28. 1–1.5 years to accrue benefits. Export receivables 90–100 days (industry standard). Working capital reduction of ~10% targeted further internally.
Chennai Phase 1 revenue ramp — Divyansh Gupta, follow-up
AnsweredPhase 1 capacity INR60 crores per annum. Phase 1 went live Aug 2025. Currently at 70% utilization on Phase 1 facility at Wada level. Phase 2 comes live Q4 FY27, adding INR50 Cr. Targeting INR15 Cr Chennai Phase 1 revenue from Q3 onward.
Capex and financing plan — Divyansh Gupta, multiple
PartialLand capex financed by accruals + internal funds (no term loan for land). Equipment capex (incremental at Wada/Chennai) may need INR40–45 Cr term loan in FY28, depending on cash position & order flow.
Solar power plant ROI — Hitesh Patel, Individual Investor
AnsweredCapex INR2.6 Cr; annual savings INR1.35 Cr (net of INR5 Cr term loan interest). Payback 4.5 years. Strategic: cost advantage + renewable export credential (CBAM compliance benefit).
Guidance
FY27 revenue growth 20–25% (maintained)
MediumQ2 beat at +31.3%, but guidance unchanged. Suggests management hedging for Q3/Q4 comps & macro uncertainty.
EBITDA margin 17–19% (maintained)
MediumQ2 at 16.76% (135 bps improvement YoY). Targeting further recovery via mix, manpower leverage, Chennai ramp. Headwinds: higher manpower cost for Europe/US expansion, forex volatility.
FY28 capex ₹40–45 Cr (new facility capex)
HighMajority for land acquisition Wada & Chennai Phase 2. Equipment capex for incremental capacity at existing sites. Financing via accruals + term loan (if required).
Risks the call surfaced
Execution risk: Capacity ramp
MediumChennai Phase 1 (₹15 Cr revenue target Q3) and Phase 2 (₹50 Cr capacity, Q4 FY27 launch) timelines are aggressive. Delays in commissioning or ramp-up would miss revenue & margin targets.
Land acquisition & approval delays
MediumWada 10-acre land MOU signed June 2026; legal finalization ongoing (draft agreement shared, some delays expected). Additional 3–5 acres for Q3–Q4 FY28 still in SIPCOT application stage (2 online filings pending).
Working capital intensity
MediumInventory & trade receivables grew sharply H1 due to 36% export mix (goods-in-transit = 90–100 DPO cycle) + 25% volume growth. OCF modest vs profitability. KPMG study on optimization ongoing; benefits 1–1.5 years away.
Electrolyzer customer concentration
MediumElectrolyzer order (₹2 Cr FY27) is from 1 global OEM. Upside ₹40–50 Cr over 2–3 years depends on 2 additional customers transitioning from sample to order. Market adoption of electrolyzer tech in India/global still nascent.
Export exposure & forex volatility
LowExport 36% of H1 revenue. H1 benefited from forex tailwind (no loss in H1 FY27 vs forex loss in H1 FY26). H2 currency movement could offset or enhance gains. New export markets (USA, Europe) scaling, so forex sensitivity will remain.
Management
Score 7/10. Direct, detailed on capacity plans & customer wins. Transparent on margin drivers (mix, manpower, forex). Minimal evasion; hedges appropriately on regulatory timelines & macro uncertainty. On track on major commitments: Chennai Phase 1 live (Aug 2025), Phase 2 Q4 FY27 confirmed. Order book >₹100 Cr validates demand. Q2 beat guidance (31% vs 20–25%), but maintained range rather than raising—prudent but also signals caution.
1 · Q3 FY27 (Oct–Dec 2026)
Chennai Phase 1 ramp-up to ₹15 Cr revenue run-rate
2 · Q4 FY27 (Jan–Mar 2027)
Chennai Phase 2 comes live; incremental ₹50 Cr capacity
3 · FY28 (Apr 2027+)
Electrolyzer orders scaled 2–3x (₹40–50 Cr potential); Wada expansion capex ₹40–45 Cr
Recommend Hold pending Q3 delivery on Chennai ramp-up.
31% Growth, Margins Lag, Guidance Unmoved
Gala beat Q2 revenue guidance handily but maintained full-year guidance rather than raising it—a cautious stance that reflects margin headwinds and execution risk ahead.
₹93.7 Cr
+31.3% YoY
20–25% growth
Maintained, not raised
16.7%
vs 17–19% target
₹100+ Cr
+44% YoY
Gala Precision reported its strongest quarter in years—₹93.7 crore in revenue, up 31.3% year-on-year—and the order book crossed ₹100 crore for the first time. By any surface read, a blowout. Yet on the call, management reiterated full-year guidance (20–25% growth, 17–19% EBITDA margin) rather than raising it. That gap—the beat on the quarter, the unchanged outlook—is where the real story sits.
The volume story is real
Management broke down the 31% revenue growth into three roughly equal pillars: organic growth driven by volume (about 10%), new components sold to existing customers (about 10%), and new customer acquisition (about 10%). The order book grew 44% year-on-year, hitting ₹100 crore—a milestone that validates momentum across all three channels. Disc springs (DSS), the core product line, remains at 85% utilization; sheet fasteners, the newer segment, is expanding into offshore wind and auto. Electrolyzer—a new application market—generated a ₹2 crore order in H1 FY27, with ₹40–50 crore potential over 2–3 years if two more OEMs move from samples to orders.
But margins fell short of target
The tension emerges here. EBITDA margin landed at 16.7%—up 135 basis points year-on-year, a solid improvement—but below the 17–19% target management had guided. Why? Management cited two offsetting pressures: product mix is improving (good), and automation is helping manpower costs (good), but headcount additions for Europe and US market expansion are eating into those gains. H1 also benefited from no forex loss (versus a forex loss in H1 FY26), a tailwind unlikely to repeat in H2. The margin lag is not a one-off; it signals the near-term challenge: converting volume growth into margin recovery takes time.
Revenue growth 31% YoY from organic + new SKUs + new customer (3 pillars ~10% each)
Delivered ₹93.7 Cr, +31.3% YoY. Breakdown credible; each pillar validated.
Supported
Order book >₹100 Cr, 44% YoY growth
Cited as major milestone; 44% YoY growth is substantive and confirmed.
Supported
PAT ₹11 Cr at 11.31% margin
Delivered ₹10.6 Cr (+26.1% YoY), margin 11.1% per result. PAT slightly lower than claimed.
Slightly overstated
EBITDA margin 16.7%, targeting 17–19%
Delivered 16.7% OPM. Guidance range maintained from prior, not raised.
Supported
Chennai Phase 1 ramp to ₹15 Cr revenue from Q3; Phase 2 live Q4 FY27
Timeline credible given capex milestones. Phase 1 already live (Aug 2025); Phase 2 ₹50 Cr capacity on track.
Supported
On track for 25% revenue growth this year
Q2 delivered 31%, well above guidance midpoint. Statement aligns with range.
Supported
What changed on this call
Electrolyzer entry: First bulk order (₹2 Cr H1 FY27) secured from a global OEM; two more in sample-development stage. Opens structural upside (₹100+ crore customer potential over 2–3 years) but carries concentration risk: the ₹2 crore is single-source, not yet diversified. Order book inflection: Hit ₹100 crore for the first time. Management highlighted as a major milestone; 44% year-on-year growth is substantive and validates 3-channel strategy (organic, new SKU, new customer). Land acquisition: 10-acre parcel at Wada secured (MOU signed June 2026); legal finalization ~95% complete. Additional 3–5 acres being pursued via SIPCOT application (pending approval). Unlocks path to ₹550 crore capacity by end FY27 (vs. ₹450 crore today). Capacity milestones: Chennai Phase 1 live (Aug 2025); Phase 2 (₹50 crore capacity) targeted Q4 FY27. Phase 1 expected to ramp to ₹15 crore revenue run-rate from Q3. FY27 guidance maintained: Revenue growth 20–25%, EBITDA margin 17–19%, unchanged from prior call. Despite beating Q2 at 31%, management kept guidance unchanged—a cautious stance that flags execution risk on capacity ramp-ups and working capital headwinds.
Order book >₹100 Cr (44% YoY) validates 3-channel strategy
Electrolyzer ₹100+ Cr customer potential (₹2 Cr order in hand)
Capacity expansion concrete (Phase 1 live, Phase 2 Q4 FY27, Wada land secured)
Renewable-sector tailwind structural, not cyclical
EBITDA margin lagging target (16.7% vs 17–19%), recovery gradual
Working capital drag >₹11 Cr H1; KPMG fix benefits 1–1.5 years out
Guidance maintained despite beat suggests caution on H2 comps
Electrolyzer ₹2 Cr from single OEM; concentration risk real
Wada land approvals for 3–5 acres pending; execution risk on new sites
Margin recovery slower than guided
MediumEBITDA margin at 16.7% vs 17–19% target. Manpower cost additions for market expansion offsetting product mix gains. If margin doesn't recover in Q3/Q4, consensus and ratings pressure will follow.
Execution risk on capacity ramp-ups
MediumChennai Phase 1 must hit ₹15 Cr revenue run-rate from Q3; Phase 2 live Q4 FY27. If either slips, FY27 revenue and margin guidance both at risk. Also depends on demand staying strong.
Working capital intensity into FY28
MediumInventory and receivables absorbed >₹11 Cr H1 cash due to 36% export mix (goods-in-transit) and 25% volume growth. KPMG fix 1–1.5 years away. If growth slows, working capital becomes a cash trap.
Electrolyzer customer concentration
Medium₹2 Cr order in H1 from single OEM. ₹40–50 Cr potential over 2–3 years depends on 2 more OEMs moving from sample to order. If scaling stalls, upside evaporates.
Land acquisition delays at Wada
Low-Medium10 acres secured; 3–5 more sought via SIPCOT application (pending approval). If SIPCOT delays, ₹550 Cr capacity target by Q4 FY27 is missed; alternate site would push timeline.
Forex headwind normalization in H2
LowH1 saw no forex loss (vs H1 FY26 loss). 36% export revenue exposure. H2 currency normalization could offset margin tailwind.
Stock is overbought; near-ATH valuation
LowRSI 72.4 (overbought); stock trading 15.66% below ATH. Margin lag could trigger profit-taking. Risk/reward near-term skews toward caution until Q3 data arrives.
How the street is positioned
The stock has rallied sharply: up 85.98% from its 52-week low (₹671.2), though now 15.66% below its all-time high of ₹1480. At ₹1248.3, it trades above its 20-day (₹1087), 50-day (₹1082), and 200-day (₹947) moving averages—a bullish technical setup. However, the RSI at 72.4 signals overbought conditions; the beat may already be priced in. Institutional ownership is stable and modest: FII at 1.30%, DII at 5.78%, promoter 54.34%. No significant rotation or insider selling; a recent bulk transaction by NK Securities (buy at ₹1041.63 / sell at ₹1042.38) shows no directional signal. Volume is increasing, suggesting fresh demand, but near-ATH valuations leave little room for disappointment. The market's message: the growth story is believed, but execution now matters.
1 · Q3 Chennai Phase 1 ramp-up
Target is ₹15 crore revenue run-rate. Delivery here is the first real test of capacity expansion roadmap and demand sustainability. Miss signals execution risk on Phase 2 and broader capex plan.
2 · EBITDA margin recovery trajectory
Must move toward 17–19% target. If Q3 margin dips further, it flags that manpower additions and forex headwinds are structural, not transient. Margin recovery is the linchpin of the bull case.
3 · Electrolyzer order scaling (2nd/3rd OEM transition)
Sample stage must convert to orders by Q3/Q4. If the two additional OEMs remain in pilot phase, the ₹40–50 Cr upside becomes a 2026+ story, not 2027.
4 · Working capital inflection
H1 absorbed >₹11 Cr. If H2 shows further deterioration or flat trajectory, KPMG's 1–1.5 year timeline becomes a cash drag risk, not a recovery story.
Gala Precision is executing against a real growth thesis: order book inflection, sector tailwinds, and capacity expansion all validate the multi-year narrative. Yet the quarter also reveals the near-term challenge: volume growth is real, but margin recovery is lagging, and guidance maintenance (not an upgrade) suggests management sees execution and macro risk ahead.
This is not a step-change story; it is steady execution with margin recovery as the critical prove-out. The stock is fairly valued at near-ATH levels, pricing in the growth consensus. Hold pending Q3 delivery on Chennai ramp-up. The single number to track from here is EBITDA margin trajectory—if it moves toward the 17–19% target, the bull case hardens; if it dips, the narrative fractures.